Treatment with rhIGF1 was employed to increase growth velocity and height and to palliate bone loss in prepubertal patients with PAPP-A2 deficiency [49,53,56,87]. This evidence concerns the gene PAPPA2 and hyperinsulinemic hypoglycemia, familial, 4.